Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at $3,951,157.35. This trade represents a 2.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Adam Laponis also recently made the following trade(s):
- On Wednesday, May 21st, Adam Laponis sold 936 shares of Twist Bioscience stock. The shares were sold at an average price of $29.75, for a total value of $27,846.00.
Twist Bioscience Price Performance
Shares of TWST traded down $0.23 during trading hours on Monday, hitting $37.80. 1,347,602 shares of the company were exchanged, compared to its average volume of 972,594. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -11.63 and a beta of 2.41. Twist Bioscience Corporation has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. The firm's fifty day moving average is $33.36 and its 200 day moving average is $39.78.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. On average, equities analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms recently weighed in on TWST. JPMorgan Chase & Co. dropped their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird dropped their price target on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group dropped their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Barclays dropped their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, Guggenheim reiterated a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $50.40.
Read Our Latest Analysis on TWST
Institutional Trading of Twist Bioscience
Large investors have recently modified their holdings of the stock. Versant Capital Management Inc boosted its stake in Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after buying an additional 580 shares in the last quarter. GAMMA Investing LLC boosted its stake in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after buying an additional 303 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Twist Bioscience during the fourth quarter valued at about $43,000. GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience during the fourth quarter worth about $58,000. Finally, US Bancorp DE grew its holdings in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after purchasing an additional 601 shares during the last quarter.
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Read More
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
